INDIVIDUALIZED
NK CELL THERAPIES
XNK Therapeutics – developing individualized NK cell therapies
We are focusing our efforts on preventing and curing cancer by developing individualized NK cell therapies. We strongly believe that our technology platform and leading investigational drug candidate, CellProtect, has the ideal properties for being a critical component in tomorrow’s cancer prevention strategies and treatments.
Pipeline
CellProtect, autologous ex vivo expanded and activated Natural killer (NK) cells with restored cytotoxicity, is our leading investigational drug candidate. Cellprotect is intended to be administered to the patient by infusions in open care.
Technology
The company owns assets related to the investigational drug product, manufacturing technology as well as combination treatment of NK cells and anti-viral agents for preventing herpes virus reactivation.
